Landry Robert E 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Feb 6, 2024
Insider Transaction Report
Form 4
Landry Robert E
SVP Fin, Dep CFO
Transactions
- Tax Payment
Common Stock
2024-02-02$956.65/sh−281$268,819→ 23,693 total - Exercise/Conversion
Common Stock
2024-02-02$378.98/sh+400$151,592→ 23,974 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-02-02−400→ 11,787 totalExercise: $378.98Exp: 2027-12-12→ Common Stock (400 underlying)
Holdings
- 270(indirect: By 401(k))
Common Stock
Footnotes (1)
- [F1]The stock option award vests in four equal annual installments, commencing one year after the date of grant.